Acute Intermittent Porphyria - Global Strategic Business Report

The global market for Acute Intermittent Porphyria was valued at US$4.7 Million in 2025 and is projected to reach US$5.7 Million by 2032, growing at a CAGR of 2.9% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Acute Intermittent Porphyria Market - Key Trends & Drivers Summarized

Why Is Acute Intermittent Porphyria Attracting Increasing Attention in the Rare Disease and Orphan Drug Space?

Acute Intermittent Porphyria (AIP) is a rare genetic metabolic disorder resulting from a deficiency of the enzyme porphobilinogen deaminase, leading to the accumulation of toxic porphyrin precursors in the body. Characterized by potentially life-threatening neurovisceral attacks, AIP typically presents with symptoms such as severe abdominal pain, vomiting, muscle weakness, confusion, and seizures. These episodic flare-ups are often triggered by factors like hormonal fluctuations, certain medications, fasting, alcohol, and infections. Given the complexity, unpredictability, and severity of the condition, early diagnosis and effective disease management are critical yet remain significantly underdeveloped in most global healthcare systems.

The rarity of AIP, with an estimated symptomatic prevalence of 5 to 10 cases per million population, places it firmly in the domain of orphan diseases. However, growing awareness of rare diseases, expanded genetic screening programs, and improved diagnostic protocols are increasing the recognition and reporting of AIP cases. Moreover, as health systems and pharmaceutical companies focus on unmet needs in precision medicine, AIP is gaining prominence due to its well-defined molecular pathology and potential for targeted therapies. The inclusion of AIP in national rare disease frameworks and orphan drug designations is helping drive market interest and research funding.

How Are Advancements in Treatment Modalities and Genetic Research Reshaping Therapeutic Pathways?

Therapeutic innovation in AIP has been catalyzed by the approval and ongoing development of targeted therapies that address the underlying biochemical disruption rather than just managing symptoms. Hemin-based treatments, such as heme arginate and lyophilized hematin, remain the standard of care for acute attacks, replenishing the heme pool and downregulating the hepatic production of porphyrin precursors. However, limitations including IV administration, side effects, and accessibility issues have highlighted the need for more patient-friendly and preventive options.

A major breakthrough has been the development of RNA interference (RNAi)-based therapies. Givosiran, an FDA- and EMA-approved RNAi drug, offers prophylactic treatment by reducing the expression of ALAS1 - the rate-limiting enzyme upstream in the heme biosynthesis pathway - thereby decreasing the frequency and severity of AIP attacks. Its subcutaneous delivery and demonstrated efficacy have marked a new chapter in chronic disease management for AIP. Parallel advancements in gene therapy and mRNA-based technologies are also being explored for long-term or curative interventions, particularly as next-generation sequencing makes personalized and mutation-specific treatment approaches more viable.

What Patient Needs, Diagnostic Challenges, and Clinical Priorities Are Driving Demand for Better Management Solutions?

Despite recent progress, the AIP landscape is still defined by diagnostic delays, misdiagnosis, and fragmented care pathways. Patients often experience multiple hospitalizations before receiving a definitive diagnosis, due to symptom overlap with more common conditions like irritable bowel syndrome, epilepsy, or psychiatric disorders. This diagnostic latency contributes to increased disease burden, long-term complications such as chronic kidney disease or hypertension, and decreased quality of life. There is a growing call for enhanced clinical awareness, early biochemical screening, and integration of genetic testing into emergency care protocols to identify AIP more rapidly and accurately.

From a patient perspective, the need for accessible, non-invasive, and preventive therapies is critical. Frequent hospital visits for IV treatments, limited specialist availability, and a lack of multidisciplinary support can make AIP management highly disruptive. This is driving interest in self-administered treatments, home care models, and digital health tools for symptom tracking and trigger avoidance. Health advocacy organizations are also raising awareness about the mental health impacts of living with a rare and unpredictable illness, prompting a more holistic approach to treatment planning that includes psychological support, patient education, and lifestyle guidance.

What Is Driving the Growth of the Acute Intermittent Porphyria Market Across Geographies and Therapeutic Channels?

The growth in the acute intermittent porphyria market is driven by advancements in rare disease therapeutics, increased global focus on orphan drug development, and the rising availability of molecular diagnostics. In North America, particularly the U.S., strong regulatory support through orphan drug designation, fast-track approvals, and financial incentives is fostering drug innovation. The presence of specialized treatment centers and active patient registries also facilitates research and market adoption. In Europe, national health systems in Germany, the UK, and the Nordics are integrating AIP care pathways into rare disease networks, improving access to advanced therapies and diagnostics.

Asia-Pacific is gradually emerging as a target region for awareness campaigns, diagnostic infrastructure improvement, and market expansion, though underdiagnosis remains a significant barrier. Japan and South Korea are leading in terms of policy support and rare disease research funding. Latin America and the Middle East are in earlier stages of development but are seeing progress through medical education programs and collaborative research partnerships aimed at improving disease visibility.

Segment-wise, the market is driven by both acute management drugs (like hemin products) and chronic prophylactic treatments (such as RNAi therapeutics). Specialty pharmacies, hospital outpatient clinics, and rare disease centers are key distribution channels. As real-world data accumulates around long-term treatment outcomes and as gene-targeted therapies advance through the pipeline, the AIP treatment landscape is expected to evolve from reactive crisis management to proactive disease suppression. This marks a turning point for the global acute intermittent porphyria market - transforming it into a rapidly maturing segment within the broader rare metabolic disorder therapeutics domain.

Report Scope

The report analyzes the Acute Intermittent Porphyria market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Diagnosis (Blood Tests, Urine Tests, DNA Tests, Serum Tests); Treatment (Gonadotropin-Releasing Hormone Analogues, Prophylactic Hematin Infusions); End-Use (Hospitals, Clinics, Research Centers)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Blood Tests segment, which is expected to reach US$2.4 Million by 2032 with a CAGR of a 2.3%. The Urine Tests segment is also set to grow at 3.9% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $1.3 Million in 2025, and China, forecasted to grow at an impressive 4.9% CAGR to reach $1.1 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Acute Intermittent Porphyria Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Acute Intermittent Porphyria Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Acute Intermittent Porphyria Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Alnylam Pharmaceuticals, Inc., Apellis Pharmaceuticals, AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Acute Intermittent Porphyria market report include:

• Alnylam Pharmaceuticals, Inc.
• Apellis Pharmaceuticals
• AstraZeneca PLC
• Bausch Health Companies Inc.
• Bayer AG
• BioMarin Pharmaceutical Inc.
• Cardinal Health
• Dicerna Pharmaceuticals
• LabCorp
• Lupin Ltd.
• Mayo Clinic Laboratories
• McKesson Corporation
• Moderna, Inc.
• Octapharma AG
• Pfizer Inc.
• Quest Diagnostics
• Recordati Rare Diseases
• Sanofi Genzyme
• Sun Pharmaceutical Industries Ltd.
• Swedish Orphan Biovitrum AB (Sobi)

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.